Acurx Gets FDA Conditional Acceptance, U.S. Patents Trademark Allowance For Ibezapolstat Brand Name

Acurx Pharmaceuticals (ACXP) said the FDA has conditionally accepted CIFBEZY as the proposed proprietary name for its lead antibiotic candidate Ibezapolstat. The conditional name acceptance is a positive regulatory milestone, though it does not by itself confirm approval or timing. Net impact is likely modest unless further FDA action follows.

Analysis

Acurx Pharmaceuticals (ACXP) said the FDA has conditionally accepted CIFBEZY as the proposed proprietary name for its lead antibiotic candidate Ibezapolstat. The conditional name acceptance is a positive regulatory milestone, though it does not by itself confirm approval or timing. Net impact is likely modest unless further FDA action follows.